The EPS miss and accelerating cash burn without a clear funding path for Phase 2b are negative signals. Monitor the May 18 CRC review for Cohort 1 safety data, a positive read could provide a near-term catalyst, but the fundamental cash constraint limits upside until a financing event occurs.
SKYE drugs
SKYE drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $0.8140entry
- T+1 · 6mo ago +0.74%α +0.16% · $0.8200
- T+5 · 6mo ago −4.42%α −4.50% · $0.7780
- T+20 · 5mo ago −4.18%α −2.45% · $0.7800
- T+60 · 3mo ago −42.05%α −46.44% · $0.4717
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Skye Bioscience reported Q1 2026 EPS of -$0.32, missing consensus of -$0.29 by 10.3%, with a net loss of $12.5M vs $11.1M a year ago. The company highlighted clinical progress in its CBeyond expansion study for nimacimab but faces a cash runway only through Q4 2026, excluding Phase 2b costs, creating significant funding uncertainty.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.32 vs consensus -$0.29 (10.3% miss)
- Net loss widened to $12.5M from $11.1M YoY
- Cash, equivalents and short-term investments: $17.1M as of March 31, 2026
- Cash runway only through Q4 2026, excluding Phase 2b costs
- R&D expenses rose to $7.9M from $7.2M YoY
- CBeyond Expansion Study Cohort 1 enrollment initiated; CRC review May 18, 2026
- Topline data from CBeyond Expansion Study expected Q4 2026
- Weighted average shares outstanding: 39.7M (basic and diluted)
Financial Impact
EPS miss of $0.03 per share; net loss increased by $1.4M YoY; cash burn rate ~$4.3M/month
Risk Factors
- Cash runway only through Q4 2026, requiring dilutive financing or partnership to fund Phase 2b
- EPS miss of 10.3% vs consensus signals operational underperformance
- Net loss widening YoY with no near-term revenue prospects
- Clinical trial risk: nimacimab may fail to meet safety/efficacy endpoints in expansion study
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293281 |
Track record
16 reports on SKYE
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +82.80% at T+60 after the Aug 14, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago DEFA14A Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
- Oct 26, 202621d ago PREM14A Bearish 7/10 Entry $1.45 Now $1.07 +26.55% settles Nov 24
- Oct 14, 20264w ago SC 13G Neutral 4/10 Entry $1.59 to $1.08 Now $1.07 −33.02% ▼ −32.08% −30.17% vs SPY
- Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $1.67 to $1.54 Now $1.07 −36.23% ▼ −7.78% −6.31% vs SPY
- Sep 24, 20267w ago SC 13D/A Bearish 6/10 Entry $1.67 to $1.54 Now $1.07 +36.23% ▲ +7.78% +6.31% vs SPY
- Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $1.78 to $1.53 Now $1.07 +40.17% ▲ +14.04% +13.14% vs SPY
- Aug 19, 202612w ago DEFA14A Neutral 4/10 Entry $0.2809 to $0.2206 Now $1.07 +279.14% ▼ −21.46% −21.34% vs SPY
- Aug 14, 202613w ago 8-K Mixed 7/10 Entry $0.5015 to $0.2487 Now $1.07 +112.36% ▼ −50.40% −48.41% vs SPY
- Aug 14, 202613w ago Press Release Bearish 7/10 Entry $0.5015 to $0.2487 Now $1.07 −112.36% ▲ +50.40% +48.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers